Drug Development

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

With a major capital infusion, the biotech firm will accelerate its lead drug for Eosinophilic Esophagitis and expand its innovative Diffusphere™ platform.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

With no approved nonsurgical options for plantar fibromatosis, Keenova's new study and late-stage trial offer a significant glimmer of hope for sufferers.

AI biotech firm Juvenescence hires a top CTO and moves into Abu Dhabi, aiming to unlock anti-aging secrets with massive genomic data and AI.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

A new "smart bomb" cancer drug, PB-223, shows complete tumor eradication with minimal toxicity in preclinical studies, setting the stage for a new battle.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.